TORONTO, Aug. 24, 2021 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) (“Mindset” or the “Company”), a drug discovery and development company focused on creating optimized and patentable next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs, today announced that it has filed its new provisional patent application with…


Previous articleCB Therapeutics Expands Biomanufacturing IP Portfolio
Next articleSame But Different: Antidepressant Mechanisms of Psilocybin and Ketamine